公开(公告)号：US20140038940A1

公开(公告)日：2014-02-06

申请号：US13843554

申请日：2013-03-15

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao XU ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/519 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04 ,  A61K2300/00

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract translation: 本发明涉及某些吡咯并嘧啶衍生物，含有它们的药物组合物及其使用方法，包括治疗肿瘤的方法和与激酶失调相关的相关疾病（如EGFR（包括HER），Alk，PDGFR），但是 途径。

公开(公告)号：US10562918B2

公开(公告)日：2020-02-18

申请号：US15882924

申请日：2018-01-29

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: C07D519/00 ,  C07D403/12 ,  C07D417/12 ,  C07D473/18 ,  C07D487/04 ,  C07D401/12 ,  C07D239/52 ,  C07D239/49 ,  C07D239/48 ,  C07D239/47

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

公开(公告)号：US09623027B2

公开(公告)日：2017-04-18

申请号：US14712794

申请日：2015-05-14

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04 ,  A61K45/06

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US09586965B2

公开(公告)日：2017-03-07

申请号：US14420341

申请日：2013-07-11

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61P29/00 ,  A61P17/06

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Abstract translation: 本发明涉及某些吡咯并嘧啶衍生物，含有它们的药物组合物及其使用方法，包括治疗增殖紊乱和与激酶失调相关的其它疾病的方法（例如但不限于EGFR（包括HER ），Alk，PDGFR，BLK，BMX / ETK，BTK，FLT3（D835Y），ITK，JAK1，JAK2，JAK3，TEC和TXK）和/或各自的途径。

公开(公告)号：US20150210702A1

公开(公告)日：2015-07-30

申请号：US14420341

申请日：2013-07-11

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Abstract translation: 本发明涉及某些吡咯并嘧啶衍生物，含有它们的药物组合物及其使用方法，包括治疗增殖紊乱和与激酶失调相关的其它疾病的方法（例如但不限于EGFR（包括HER ），Alk，PDGFR，BLK，BMX / ETK，BTK，FLT3（D835Y），ITK，JAK1，JAK2，JAK3，TEC和TXK）和/或各自的途径。

公开(公告)号：US09763949B2

公开(公告)日：2017-09-19

申请号：US14712794

申请日：2015-05-14

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  A61K45/06 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04 ,  A61K2300/00

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US09464089B2

公开(公告)日：2016-10-11

申请号：US14329890

申请日：2014-07-11

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/506 ,  C07D241/04 ,  C07D239/30 ,  C07D487/04 ,  C07D239/52 ,  C07D239/49 ,  C07D403/12 ,  C07D401/12 ,  C07D473/18 ,  C07D417/12

CPC classification number: C07D519/00 ,  C07D239/47 ,  C07D239/48 ,  C07D239/49 ,  C07D239/52 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D473/18 ,  C07D487/04

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Abstract translation: 本发明涉及药物化合物，组合物和方法，特别是因为它们与用于治疗和/或预防增殖病症，癌症，肿瘤，炎性疾病，自身免疫性疾病，牛皮癣，干性疾病的组合物和方法有关 眼睛或免疫相关疾病，在一些实施方案中，与激酶失调相关的疾病或病症，例如但不限于EGFR（包括HER），Alk，PDGFR，BLK，BMX / ETK，FLT3（D835Y），ITK ，TEC，TXK，BTK或JAK，以及各自的途径。

公开(公告)号：US09034885B2

公开(公告)日：2015-05-19

申请号：US13843554

申请日：2013-03-15

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/04 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04 ,  A61K2300/00

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract translation: 本发明涉及某些吡咯并嘧啶衍生物，含有它们的药物组合物及其使用方法，包括治疗肿瘤的方法和与激酶失调相关的相关疾病（如EGFR（包括HER），Alk，PDGFR），但是 途径。

公开(公告)号：US10799504B2

公开(公告)日：2020-10-13

申请号：US13740182

申请日：2013-01-12

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/506 ,  C07D401/14 ,  C07D403/12 ,  A61K45/06 ,  C07D239/42 ,  C07D401/12 ,  A61K31/519 ,  A61K31/52 ,  C07D473/32 ,  C07D487/04 ,  C07D473/34 ,  C07D239/48 ,  C07D473/24 ,  C07D239/46 ,  C07D473/40 ,  C07D487/02 ,  C07D473/16 ,  C07D239/47

Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US10596174B2

公开(公告)日：2020-03-24

申请号：US15435722

申请日：2017-02-17

Applicant: ACEA BIOSCIENCES INC.

Inventor： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC: A61K31/519 ,  C07D487/04 ,  A61K31/52 ,  A61K31/506 ,  C07D473/32 ,  C07D401/14 ,  C07D473/34 ,  C07D403/12 ,  C07D239/46 ,  C07D239/42 ,  C07D239/47 ,  C07D473/40 ,  C07D487/02 ,  C07D401/12 ,  C07D239/48 ,  C07D473/16 ,  C07D473/24 ,  A61K45/06

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.